Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

Second Asset To Enter Clinic In 2026

 
• By Mandy Jackson
  
Ollin has a drug in Phase Ib and another nearing the clinic, but continues to hunt for additional ophthalmology assets (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business